Dr. Leo Kim is the Founder and CEO of Higher Medicine. Leo has served in various biopharma R&D and operations roles at McKinsey, Baxter/Baxalta, and AstraZeneca. PhD in Neuroscience from Penn by training, Leo brings the unique combination of scientific acumen, strategic chop, and operational fluency to establish the clinical program and build a winning team for HMD patients & investors

John Glasspool is the Chief Executive Officer at VarmX and serves as a Board Director and Executive Advisor at HMD. John brings decades of industry leadership and founded Anthos Therapeutics to apply a clinically-validated Novartis molecule for a new indication via a private equity investment, and successfully shepherded it through positive Phase 2 human efficacy data generation.

Claude Knopf is the Chief Business Officer at Imcheck Therapeutics and serves as a Board Director and BD&L Advisor at HMD. Claude held a number of high-profile Business Development and similar roles across the industry for over 30 years, including Baxter/Baxalta, Novartis, and Merck.

Deborah Peirce is the Managing Partner of WindSail Insights, an HR consultancy, and serves as a Board Directo and Talent Advisor at HMD. Deborah brings over two decades of team building and people management skillsets across industries, including Motorola, Baxter/Baxalta, Teva, and Anthos. Deborah was instrumental in creating the early R&D team at Anthos with John Glasspool.

Timothy Dore is the Drug Development Lead at Higher Medicine, with 20+ years of experience in medicinal and bioorganic chemistry. He has led global, multidisciplinary teams in academia and industry, advancing drug discovery and pioneering molecular tools to address complex biological questions. At HMD, he is guiding clinical planning, regulatory pathway design, and operational strategy to prepare for future IND-enabling and Phase 1/2 studies.